1	Genentech	_	NNP	_	_	3	SBJ	_	_
2	Inc.	_	NNP	_	_	1	POSTHON	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	third-quarter	_	JJ	_	_	5	NMOD	_	_
5	profit	_	NN	_	_	8	SBJ	_	_
6	more	_	RBR	_	_	8	ADV	_	_
7	than	_	IN	_	_	6	AMOD	_	_
8	doubled	_	VBD	_	_	3	OBJ	_	_
9	to	_	TO	_	_	8	DIR	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	11.4	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	,	_	,	_	_	10	P	_	_
14	or	_	CC	_	_	10	COORD	_	_
15	13	_	CD	_	_	16	NMOD	_	_
16	cents	_	NNS	_	_	14	CONJ	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	16	ADV	_	_
19	,	_	,	_	_	10	P	_	_
20	from	_	IN	_	_	8	DIR	_	_
21	a	_	DT	_	_	25	NMOD	_	_
22	depressed	_	JJ	_	_	25	NMOD	_	_
23	1988	_	CD	_	_	25	NMOD	_	_
24	third-quarter	_	JJ	_	_	25	NMOD	_	_
25	performance	_	NN	_	_	20	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	$	_	$	_	_	26	PMOD	_	_
28	5.3	_	CD	_	_	27	DEP	_	_
29	million	_	CD	_	_	27	DEP	_	_
30	,	_	,	_	_	27	P	_	_
31	or	_	CC	_	_	27	COORD	_	_
32	six	_	CD	_	_	33	NMOD	_	_
33	cents	_	NNS	_	_	31	CONJ	_	_
34	a	_	DT	_	_	35	NMOD	_	_
35	share	_	NN	_	_	33	ADV	_	_
36	.	_	.	_	_	3	P	_	_

1	Revenue	_	NN	_	_	2	SBJ	_	_
2	rose	_	VBD	_	_	0	ROOT	_	_
3	23	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	2	EXT	_	_
5	to	_	TO	_	_	2	DIR	_	_
6	$	_	$	_	_	5	PMOD	_	_
7	100	_	CD	_	_	6	DEP	_	_
8	million	_	CD	_	_	6	DEP	_	_
9	from	_	IN	_	_	2	DIR	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	81.6	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	.	_	.	_	_	2	P	_	_

1	Net	_	JJ	_	_	3	NMOD	_	_
2	product	_	NN	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	accounted	_	VBD	_	_	0	ROOT	_	_
5	for	_	IN	_	_	4	ADV	_	_
6	$	_	$	_	_	5	PMOD	_	_
7	76	_	CD	_	_	6	DEP	_	_
8	million	_	CD	_	_	6	DEP	_	_
9	,	_	,	_	_	4	P	_	_
10	up	_	RB	_	_	4	ADV	_	_
11	from	_	IN	_	_	10	AMOD	_	_
12	$	_	$	_	_	11	PMOD	_	_
13	57.5	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	a	_	DT	_	_	16	NMOD	_	_
16	year	_	NN	_	_	17	AMOD	_	_
17	earlier	_	RB	_	_	11	TMP	_	_
18	.	_	.	_	_	4	P	_	_

1	Sales	_	NNS	_	_	7	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	6	NMOD	_	_
4	heart	_	NN	_	_	6	NMOD	_	_
5	drug	_	NN	_	_	6	NMOD	_	_
6	TPA	_	NNP	_	_	2	PMOD	_	_
7	were	_	VBD	_	_	0	ROOT	_	_
8	$	_	$	_	_	7	PRD	_	_
9	43.6	_	CD	_	_	8	DEP	_	_
10	million	_	CD	_	_	8	DEP	_	_
11	,	_	,	_	_	8	P	_	_
12	better	_	JJR	_	_	8	APPO	_	_
13	than	_	IN	_	_	12	AMOD	_	_
14	last	_	JJ	_	_	15	NMOD	_	_
15	year	_	NN	_	_	19	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	depressed	_	JJ	_	_	19	NMOD	_	_
18	third	_	JJ	_	_	19	NMOD	_	_
19	period	_	NN	_	_	13	PMOD	_	_
20	when	_	WRB	_	_	23	TMP	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	company	_	NN	_	_	23	SBJ	_	_
23	sold	_	VBD	_	_	19	NMOD	_	_
24	just	_	RB	_	_	25	DEP	_	_
25	$	_	$	_	_	23	OBJ	_	_
26	29.1	_	CD	_	_	25	DEP	_	_
27	million	_	CD	_	_	25	DEP	_	_
28	of	_	IN	_	_	25	NMOD	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	drug	_	NN	_	_	28	PMOD	_	_
31	.	_	.	_	_	7	P	_	_

1	But	_	CC	_	_	4	DEP	_	_
2	TPA	_	NNP	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	fell	_	VBD	_	_	0	ROOT	_	_
5	below	_	IN	_	_	4	DIR	_	_
6	levels	_	NNS	_	_	5	PMOD	_	_
7	for	_	IN	_	_	6	NMOD	_	_
8	this	_	DT	_	_	9	NMOD	_	_
9	year	_	NN	_	_	15	NMOD	_	_
10	's	_	POS	_	_	9	SUFFIX	_	_
11	first	_	JJ	_	_	15	NMOD	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	second	_	JJ	_	_	12	CONJ	_	_
14	quarter	_	NN	_	_	15	NMOD	_	_
15	sales	_	NNS	_	_	7	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	$	_	$	_	_	16	PMOD	_	_
18	48	_	CD	_	_	17	DEP	_	_
19	million	_	CD	_	_	17	DEP	_	_
20	,	_	,	_	_	4	P	_	_
21	cooling	_	VBG	_	_	4	ADV	_	_
22	investors	_	NNS	_	_	21	OBJ	_	_
23	.	_	.	_	_	4	P	_	_

1	Genentech	_	NNP	_	_	2	NMOD	_	_
2	stock	_	NN	_	_	3	SBJ	_	_
3	fell	_	VBD	_	_	0	ROOT	_	_
4	12.5	_	CD	_	_	5	NMOD	_	_
5	cents	_	NNS	_	_	3	EXT	_	_
6	in	_	IN	_	_	3	LOC	_	_
7	trading	_	NN	_	_	6	PMOD	_	_
8	yesterday	_	NN	_	_	7	TMP	_	_
9	on	_	IN	_	_	7	LOC	_	_
10	the	_	DT	_	_	14	NMOD	_	_
11	New	_	NNP	_	_	14	NAME	_	_
12	York	_	NNP	_	_	14	NAME	_	_
13	Stock	_	NNP	_	_	14	NAME	_	_
14	Exchange	_	NNP	_	_	9	PMOD	_	_
15	to	_	TO	_	_	3	DIR	_	_
16	$	_	$	_	_	15	PMOD	_	_
17	20.125	_	CD	_	_	16	NMOD	_	_
18	.	_	.	_	_	3	P	_	_

1	In	_	IN	_	_	8	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	nine	_	CD	_	_	4	NMOD	_	_
4	months	_	NNS	_	_	1	PMOD	_	_
5	,	_	,	_	_	8	P	_	_
6	net	_	JJ	_	_	7	NMOD	_	_
7	income	_	NN	_	_	8	SBJ	_	_
8	slid	_	VBD	_	_	0	ROOT	_	_
9	21	_	CD	_	_	10	NMOD	_	_
10	%	_	NN	_	_	8	ADV	_	_
11	to	_	TO	_	_	8	DIR	_	_
12	$	_	$	_	_	11	PMOD	_	_
13	28.4	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	,	_	,	_	_	12	P	_	_
16	or	_	CC	_	_	12	COORD	_	_
17	33	_	CD	_	_	18	NMOD	_	_
18	cents	_	NNS	_	_	16	CONJ	_	_
19	a	_	DT	_	_	20	NMOD	_	_
20	share	_	NN	_	_	18	ADV	_	_
21	,	_	,	_	_	12	P	_	_
22	from	_	IN	_	_	8	DIR	_	_
23	$	_	$	_	_	22	PMOD	_	_
24	36	_	CD	_	_	23	DEP	_	_
25	million	_	CD	_	_	23	DEP	_	_
26	,	_	,	_	_	23	P	_	_
27	or	_	CC	_	_	23	COORD	_	_
28	42	_	CD	_	_	29	NMOD	_	_
29	cents	_	NNS	_	_	27	CONJ	_	_
30	a	_	DT	_	_	31	NMOD	_	_
31	share	_	NN	_	_	29	ADV	_	_
32	.	_	.	_	_	8	P	_	_

1	Revenues	_	NNS	_	_	2	SBJ	_	_
2	climbed	_	VBD	_	_	0	ROOT	_	_
3	18	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	2	EXT	_	_
5	to	_	TO	_	_	2	DIR	_	_
6	$	_	$	_	_	5	PMOD	_	_
7	289	_	CD	_	_	6	DEP	_	_
8	million	_	CD	_	_	6	DEP	_	_
9	from	_	IN	_	_	2	DIR	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	245.3	_	CD	_	_	10	DEP	_	_
12	million	_	CD	_	_	10	DEP	_	_
13	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	22	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	continue	_	VBP	_	_	22	OBJ	_	_
4	to	_	TO	_	_	3	OPRD	_	_
5	be	_	VB	_	_	4	IM	_	_
6	on	_	IN	_	_	5	ADV	_	_
7	target	_	NN	_	_	6	PMOD	_	_
8	for	_	IN	_	_	5	PRD	_	_
9	...	_	:	_	_	8	P	_	_
10	increasing	_	VBG	_	_	8	PMOD	_	_
11	TPA	_	NNP	_	_	12	NMOD	_	_
12	sales	_	NNS	_	_	10	OBJ	_	_
13	20	_	CD	_	_	14	NMOD	_	_
14	%	_	NN	_	_	10	OBJ	_	_
15	to	_	TO	_	_	14	NMOD	_	_
16	25	_	CD	_	_	17	NMOD	_	_
17	%	_	NN	_	_	15	PMOD	_	_
18	this	_	DT	_	_	19	NMOD	_	_
19	year	_	NN	_	_	10	DEP	_	_
20	,	_	,	_	_	22	P	_	_
21	''	_	''	_	_	22	P	_	_
22	said	_	VBD	_	_	0	ROOT	_	_
23	founder	_	NN	_	_	22	SBJ	_	_
24	and	_	CC	_	_	23	COORD	_	_
25	Chief	_	NNP	_	_	29	NAME	_	_
26	Executive	_	NNP	_	_	29	NAME	_	_
27	Officer	_	NNP	_	_	29	NAME	_	_
28	Robert	_	NNP	_	_	29	NAME	_	_
29	Swanson	_	NNP	_	_	24	CONJ	_	_
30	.	_	.	_	_	22	P	_	_

1	But	_	CC	_	_	4	DEP	_	_
2	some	_	DT	_	_	3	NMOD	_	_
3	analysts	_	NNS	_	_	4	SBJ	_	_
4	remain	_	VBP	_	_	0	ROOT	_	_
5	sour	_	JJ	_	_	4	PRD	_	_
6	on	_	IN	_	_	5	AMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	company	_	NN	_	_	6	PMOD	_	_
9	.	_	.	_	_	4	P	_	_

1	``	_	``	_	_	4	P	_	_
2	TPA	_	NNP	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	are	_	VBP	_	_	0	ROOT	_	_
5	down	_	RB	_	_	4	PRD	_	_
6	quarter	_	NN	_	_	4	TMP	_	_
7	to	_	TO	_	_	6	NMOD	_	_
8	quarter	_	NN	_	_	7	PMOD	_	_
9	.	_	.	_	_	4	P	_	_

1	Expenses	_	NNS	_	_	2	SBJ	_	_
2	are	_	VBP	_	_	0	ROOT	_	_
3	flat	_	JJ	_	_	2	PRD	_	_
4	and	_	CC	_	_	2	COORD	_	_
5	that	_	DT	_	_	6	SBJ	_	_
6	's	_	VBZ	_	_	4	CONJ	_	_
7	a	_	DT	_	_	9	NMOD	_	_
8	good	_	JJ	_	_	9	NMOD	_	_
9	sign	_	NN	_	_	6	PRD	_	_
10	.	_	.	_	_	2	P	_	_

1	There	_	EX	_	_	2	SBJ	_	_
2	's	_	VBZ	_	_	0	ROOT	_	_
3	contract	_	NN	_	_	4	NMOD	_	_
4	revenue	_	NN	_	_	2	PRD	_	_
5	from	_	IN	_	_	4	NMOD	_	_
6	{	_	(	_	_	8	P	_	_
7	limited	_	JJ	_	_	8	NMOD	_	_
8	research	_	NN	_	_	5	PMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	development	_	NN	_	_	9	CONJ	_	_
11	}	_	)	_	_	10	P	_	_
12	partnerships	_	NNS	_	_	10	COORD	_	_
13	.	_	.	_	_	2	P	_	_

1	But	_	CC	_	_	4	DEP	_	_
2	I	_	PRP	_	_	4	SBJ	_	_
3	still	_	RB	_	_	4	ADV	_	_
4	think	_	VBP	_	_	11	OBJ	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	fundamentals	_	NNS	_	_	7	SBJ	_	_
7	are	_	VBP	_	_	4	OBJ	_	_
8	poor	_	JJ	_	_	7	PRD	_	_
9	,	_	,	_	_	11	P	_	_
10	''	_	''	_	_	11	P	_	_
11	said	_	VBD	_	_	0	ROOT	_	_
12	Denise	_	NNP	_	_	13	NAME	_	_
13	Gilbert	_	NNP	_	_	11	SBJ	_	_
14	,	_	,	_	_	13	P	_	_
15	an	_	DT	_	_	16	NMOD	_	_
16	analyst	_	NN	_	_	13	APPO	_	_
17	with	_	IN	_	_	16	NMOD	_	_
18	Montgomery	_	NNP	_	_	19	NAME	_	_
19	Securities	_	NNPS	_	_	17	PMOD	_	_
20	in	_	IN	_	_	19	LOC	_	_
21	San	_	NNP	_	_	22	NAME	_	_
22	Francisco	_	NNP	_	_	20	PMOD	_	_
23	.	_	.	_	_	11	P	_	_

1	Genentech	_	NNP	_	_	2	SBJ	_	_
2	faces	_	VBZ	_	_	0	ROOT	_	_
3	competition	_	NN	_	_	2	OBJ	_	_
4	in	_	IN	_	_	3	LOC	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	cardiac-drug	_	JJ	_	_	7	NMOD	_	_
7	market	_	NN	_	_	4	PMOD	_	_
8	from	_	IN	_	_	3	NMOD	_	_
9	SmithKline	_	NNP	_	_	11	NAME	_	_
10	Beecham	_	NNP	_	_	11	NAME	_	_
11	PLC	_	NNP	_	_	15	NMOD	_	_
12	's	_	POS	_	_	11	SUFFIX	_	_
13	heart	_	NN	_	_	15	NMOD	_	_
14	drug	_	NN	_	_	15	NMOD	_	_
15	Eminase	_	NNP	_	_	8	PMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	expected	_	VBN	_	_	15	APPO	_	_
18	to	_	TO	_	_	17	OPRD	_	_
19	receive	_	VB	_	_	18	IM	_	_
20	market	_	NN	_	_	21	NMOD	_	_
21	approval	_	NN	_	_	19	OBJ	_	_
22	shortly	_	RB	_	_	19	TMP	_	_
23	.	_	.	_	_	2	P	_	_

1	And	_	CC	_	_	3	DEP	_	_
2	Genentech	_	NNP	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	21	OBJ	_	_
4	n't	_	RB	_	_	3	ADV	_	_
5	likely	_	JJ	_	_	3	PRD	_	_
6	to	_	TO	_	_	5	AMOD	_	_
7	have	_	VB	_	_	6	IM	_	_
8	any	_	DT	_	_	10	NMOD	_	_
9	new	_	JJ	_	_	10	NMOD	_	_
10	products	_	NNS	_	_	7	OBJ	_	_
11	ready	_	JJ	_	_	7	OPRD	_	_
12	for	_	IN	_	_	11	AMOD	_	_
13	market	_	NN	_	_	12	PMOD	_	_
14	until	_	IN	_	_	7	TMP	_	_
15	at	_	IN	_	_	17	NMOD	_	_
16	least	_	JJS	_	_	15	AMOD	_	_
17	1992	_	CD	_	_	14	PMOD	_	_
18	,	_	,	_	_	21	P	_	_
19	Ms.	_	NNP	_	_	20	TITLE	_	_
20	Gilbert	_	NNP	_	_	21	SBJ	_	_
21	added	_	VBD	_	_	0	ROOT	_	_
22	.	_	.	_	_	21	P	_	_

1	``	_	``	_	_	24	P	_	_
2	The	_	DT	_	_	3	NMOD	_	_
3	company	_	NN	_	_	5	NMOD	_	_
4	's	_	POS	_	_	3	SUFFIX	_	_
5	stock	_	NN	_	_	6	SBJ	_	_
6	is	_	VBZ	_	_	24	OBJ	_	_
7	trading	_	VBG	_	_	6	VC	_	_
8	at	_	IN	_	_	7	ADV	_	_
9	40	_	CD	_	_	10	DEP	_	_
10	times	_	NNS	_	_	14	NMOD	_	_
11	next	_	JJ	_	_	12	NMOD	_	_
12	year	_	NN	_	_	14	NMOD	_	_
13	's	_	POS	_	_	12	SUFFIX	_	_
14	numbers	_	NNS	_	_	8	PMOD	_	_
15	,	_	,	_	_	6	P	_	_
16	and	_	CC	_	_	6	COORD	_	_
17	that	_	DT	_	_	18	SBJ	_	_
18	's	_	VBZ	_	_	16	CONJ	_	_
19	too	_	RB	_	_	20	AMOD	_	_
20	much	_	JJ	_	_	18	PRD	_	_
21	,	_	,	_	_	24	P	_	_
22	''	_	''	_	_	24	P	_	_
23	she	_	PRP	_	_	24	SBJ	_	_
24	said	_	VBD	_	_	0	ROOT	_	_
25	.	_	.	_	_	24	P	_	_

1	On	_	IN	_	_	7	ADV	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	plus	_	JJ	_	_	4	NMOD	_	_
4	side	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	7	P	_	_
6	Genentech	_	NN	_	_	7	SBJ	_	_
7	is	_	VBZ	_	_	27	OBJ	_	_
8	benefiting	_	VBG	_	_	7	VC	_	_
9	from	_	IN	_	_	8	ADV	_	_
10	a	_	DT	_	_	13	NMOD	_	_
11	lower	_	JJR	_	_	13	NMOD	_	_
12	tax	_	NN	_	_	13	NMOD	_	_
13	rate	_	NN	_	_	9	PMOD	_	_
14	due	_	JJ	_	_	15	DEP	_	_
15	to	_	TO	_	_	13	NMOD	_	_
16	its	_	PRP$	_	_	18	NMOD	_	_
17	research	_	NN	_	_	18	NMOD	_	_
18	outlays	_	NNS	_	_	15	PMOD	_	_
19	,	_	,	_	_	13	P	_	_
20	giving	_	VBG	_	_	13	APPO	_	_
21	a	_	DT	_	_	22	NMOD	_	_
22	boost	_	NN	_	_	20	OBJ	_	_
23	to	_	TO	_	_	20	DTV	_	_
24	earnings	_	NNS	_	_	23	PMOD	_	_
25	,	_	,	_	_	27	P	_	_
26	she	_	PRP	_	_	27	SBJ	_	_
27	said	_	VBD	_	_	0	ROOT	_	_
28	.	_	.	_	_	27	P	_	_

